Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary
Background: Biologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system. Objective: To conduct a cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinum...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | JAAD International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328721000456 |
| _version_ | 1819097619827261440 |
|---|---|
| author | Helen Y. Sun, BSc(Med)Hons Elena Keller, MHEcon Harish Suresh, BAct(Co-op) Deshan F. Sebaratnam, FACD |
| author_facet | Helen Y. Sun, BSc(Med)Hons Elena Keller, MHEcon Harish Suresh, BAct(Co-op) Deshan F. Sebaratnam, FACD |
| author_sort | Helen Y. Sun, BSc(Med)Hons |
| collection | DOAJ |
| description | Background: Biologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system. Objective: To conduct a cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab) available to adults with severe, chronic plaque psoriasis from the perspective of the Australian health care system. Methods: A Markov cohort model was constructed to estimate the quality-adjusted life years (QALYs) and costs accrued for treatment pathways commencing with different first-line biologics, over a 96-week time horizon. The model adhered to the Australian Pharmaceutical Benefits Scheme eligibility criteria and guidelines. Results: A biologic treatment pathway commencing on tildrakizumab was the most cost-effective first-line treatment (Australian dollar 39,930; total utility of 1.57 QALYs over 96 weeks). First-line secukinumab and risankizumab had incremental cost-utility ratios of Australian dollar 194,524/QALY and Australian dollar 479,834/QALY, respectively, when compared with first-line tildrakizumab. Limitations: The efficacy and utility input parameters were derived from international randomized control trials and patients from the United Kingdom, respectively. Findings from this study cannot be generalized beyond Australia. Conclusion: Tildrakizumab may be considered as first-line treatment for adult patients with severe, chronic plaque psoriasis embarking on biologic therapy, from the economic perspective of the Australian health care system. |
| first_indexed | 2024-12-22T00:17:59Z |
| format | Article |
| id | doaj.art-c6d6aad5b0b9407a863ed31d8beb91c8 |
| institution | Directory Open Access Journal |
| issn | 2666-3287 |
| language | English |
| last_indexed | 2024-12-22T00:17:59Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD International |
| spelling | doaj.art-c6d6aad5b0b9407a863ed31d8beb91c82022-12-21T18:45:14ZengElsevierJAAD International2666-32872021-12-01518Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule SummaryHelen Y. Sun, BSc(Med)Hons0Elena Keller, MHEcon1Harish Suresh, BAct(Co-op)2Deshan F. Sebaratnam, FACD3Faculty of Medicine and Health, The University of New South Wales, Kensington, New South Wales, Australia; Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia; Correspondence to: Helen Y. Sun, BSc(Med)Hons, Faculty of Medicine and Health, The University of New South Wales, High Street, Kensington, NSW 2052, Australia.Centre for Big Data Research in Health, The University of New South Wales, Kensington, New South Wales, AustraliaFaculty of Business, The University of New South Wales, Kensington, New South Wales, AustraliaFaculty of Medicine and Health, The University of New South Wales, Kensington, New South Wales, Australia; Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, AustraliaBackground: Biologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system. Objective: To conduct a cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab) available to adults with severe, chronic plaque psoriasis from the perspective of the Australian health care system. Methods: A Markov cohort model was constructed to estimate the quality-adjusted life years (QALYs) and costs accrued for treatment pathways commencing with different first-line biologics, over a 96-week time horizon. The model adhered to the Australian Pharmaceutical Benefits Scheme eligibility criteria and guidelines. Results: A biologic treatment pathway commencing on tildrakizumab was the most cost-effective first-line treatment (Australian dollar 39,930; total utility of 1.57 QALYs over 96 weeks). First-line secukinumab and risankizumab had incremental cost-utility ratios of Australian dollar 194,524/QALY and Australian dollar 479,834/QALY, respectively, when compared with first-line tildrakizumab. Limitations: The efficacy and utility input parameters were derived from international randomized control trials and patients from the United Kingdom, respectively. Findings from this study cannot be generalized beyond Australia. Conclusion: Tildrakizumab may be considered as first-line treatment for adult patients with severe, chronic plaque psoriasis embarking on biologic therapy, from the economic perspective of the Australian health care system.http://www.sciencedirect.com/science/article/pii/S2666328721000456adalimumabAustraliabiologic therapycost-effectiveness analysiscost-utility analysiscost-benefit analysis |
| spellingShingle | Helen Y. Sun, BSc(Med)Hons Elena Keller, MHEcon Harish Suresh, BAct(Co-op) Deshan F. Sebaratnam, FACD Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary JAAD International adalimumab Australia biologic therapy cost-effectiveness analysis cost-utility analysis cost-benefit analysis |
| title | Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary |
| title_full | Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary |
| title_fullStr | Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary |
| title_full_unstemmed | Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary |
| title_short | Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary |
| title_sort | biologics for severe chronic plaque psoriasis an australian cost utility analysiscapsule summary |
| topic | adalimumab Australia biologic therapy cost-effectiveness analysis cost-utility analysis cost-benefit analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2666328721000456 |
| work_keys_str_mv | AT helenysunbscmedhons biologicsforseverechronicplaquepsoriasisanaustraliancostutilityanalysiscapsulesummary AT elenakellermhecon biologicsforseverechronicplaquepsoriasisanaustraliancostutilityanalysiscapsulesummary AT harishsureshbactcoop biologicsforseverechronicplaquepsoriasisanaustraliancostutilityanalysiscapsulesummary AT deshanfsebaratnamfacd biologicsforseverechronicplaquepsoriasisanaustraliancostutilityanalysiscapsulesummary |